Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer (SCLC) and has been approved by the FDA for this purpose [2]. The drug works by inhibiting RNA polymerase II, which is an enzyme that is important for the transcription of DNA into RNA [3]. The FDA has approved lurbinectedin for use as a second-line treatment for SCLC [2].

However, there is limited information available regarding the extended use of lurbinectedin. While clinical trials have been conducted to test the efficacy and safety of the drug, these trials have generally been limited to a relatively short duration [1].

One study published in the journal Cancer Management and Research in 2021 reported on the results of a phase 2 clinical trial of lurbinectedin in patients with relapsed SCLC [3]. In this trial, patients received lurbinectedin once every three weeks for up to six cycles. The study found that lurbinectedin was effective in treating relapsed SCLC, with an overall response rate of 35.5% and a median progression-free survival of 3.5 months [3]. However, the study did not investigate the long-term effects of lurbinectedin treatment beyond the six-cycle limit.

Overall, while lurbinectedin has been approved by the FDA for the treatment of SCLC, there is limited information available regarding its extended use. While clinical trials have demonstrated the efficacy and safety of the drug over a relatively short duration, further research is needed to investigate the long-term effects of lurbinectedin treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674596/